roy vimer

Technical Analysis & Japanese. my main focus is identifying cutting edge biotechnology companies that undervalued. BioGroup Team Biotech Analyst

[roy vimer @roiev123]

Goldman Sachs maintained a Buy rating with a price target of $135. The analyst believes $BLUE is “entering a key value-inflection point.”

[roy vimer @roiev123]

Roth Capital lowered his PT for $CERU to $2.50 from $9. Nonetheless, He reiterates a Buy rating on the shares.

[roy vimer @roiev123]

$BLUE Piper Jaffray reduced the price target to $95, while reiterating Overweight.

[roy vimer @roiev123]

$heb 1-for-12 reverse stock split of its common stock.

[roy vimer @roiev123]

$BLCM: New Insider Filing https://t.co/6GPf01G3o2

[roy vimer @roiev123]

@tgtxdough on the other hand Canaccord Maintained BUY, $15 PT with "expectation for positive Phase 2 data for CRLX-101 mid-2016.”

[roy vimer @roiev123]

$CERU #FAIL Median PFS was 3.7 months for the CRLX101 combination compared with a median PFS of 3.9 months for SOC.

[roy vimer @roiev123]

$RMTI license with ARAM Medical for Rockwell's Triferic and Calcitriol in the Middle East

[roy vimer @roiev123]

$INO licenses a veterinary vaccine for foot and mouth disease (FMD) to Plumbline Life Sciences.

[roy vimer @roiev123]

@CopaDelMundo7 @plungeprotect HC Wainwright participated in the Mar 2015 share offering in $CYCC and he wishes to continue the relationship.

[roy vimer @roiev123]

$ONCE nice breakout today

[roy vimer @roiev123]

$URRE is definitely going to have to raise cash soon. As of August 10, they had only $0.4m #watchout

[Reuters Health @Reuters_Health]

DEA denies petition to reclassify marijuana: Federal Register https://t.co/mGo0OcRDaO

[roy vimer @roiev123]

$RDHL Another delay from the Ph III study in acute gastroenteritis and gastritis. completion of patient enrollment is expected in early 2017

[roy vimer @roiev123]

$RDHL Provides 2016 Semi-Annual R&D Update https://t.co/MTVzWWySXn

[roy vimer @roiev123]

$ARWR $45 million private offering. The offering was priced at $5.90 per share.

[roy vimer @roiev123]

@RSIDayTrader because they are using the ATM financing all the time.

[Gerb W @WilliamGerber1]

https://t.co/SUcNILUYc9 Who r @ReutersBiz sources & how could they be such complete liars & get away with it? $RLYP

[roy vimer @roiev123]

$XNCR Q2 revenue $66.0M. Q2 income is primarily due to income recognized under Xencor's Novartis and Amgen collaborations.

[roy vimer @roiev123]

@sharkbiotech Except the shorts